Premium
P4‐236: Does concomitant treatment with cholinesterase inhibitors or memantine affect cerebrolysin treatment's efficacy in Alzheimer disease? Results from the Argentinean cerebrolysin registry
Author(s) -
Previgliano Ignacio,
Kremer Janus,
Tiezzi Gerardo,
Rojas Galeno,
Tozzola Marco,
Albanese Gustavo,
Bukler Miryam,
Bosch Mauricio,
Andersson Alejandro,
Klein Ricardo,
Torres Marta,
Ponteville Christiane
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2261
Subject(s) - cerebrolysin , memantine , medicine , concomitant , cholinesterase , randomized controlled trial , statistical significance , morphea , adverse effect , dementia , disease , biopsy
O (donepezil) 21 9 0 30 21.16 1.89 I (rivastigmine) 25 9 2 36 17.42 1.73 A (gallantamine) 9 3 0 12 20.66 2 E (memantine) 14 3 1 18 18.10 0.66 OME 40 1 2 43 18.52 3.75 IME 21 9 1 31 15.85 2.26 AME 5 2 0 7 17.83 3 e (cerebrolysin) 20 4 1 25 19.47 4.68 otal 155 40 7 202 18.54 2.76 Diana Pollock, Vikram Atit, George Brewer, Steven Kanzer, Lara Guzman, David Newsome, Ptak Alzheimer’s Research Center, Clearwater, Florida, United States; Atit Neurology Institute, Holiday, Florida, United States; Adeona, Ann Arbor, Michigan, United States.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom